Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q4 EPS of ($0.39), $0.16 better than the analyst estimate of ($0.55). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $2.07 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.